Martin M Miner: Influence Statistics

Martin M Miner

Martin M Miner

Family Medicine and Urology, Warran Alpert Medical School, Brown University, Providence, Rhode Island, USA | Men’s Health Center, Miriam Hospital, Providence, RI 02906, USA;, ...

Martin M Miner: Expert Impact

Concepts for which Martin M Miner has direct influence: Erectile dysfunction , Cardiovascular disease , Cardiovascular risk , 12 months , Cardiometabolic risk , Testosterone replacement therapy , Testim registry .

Martin M Miner: KOL impact

Concepts related to the work of other authors for which for which Martin M Miner has influence: Erectile dysfunction , Prostate cancer , Testosterone therapy , Sexual function , Metabolic syndrome , Cardiovascular disease , Benign prostatic hyperplasia .

KOL Resume for Martin M Miner

Year
2022

Family Medicine and Urology, Warran Alpert Medical School, Brown University, Providence, Rhode Island, USA

2021

Men’s Health Center The Miriam Hotel, Providence, RI, USA

2020

Men’s Health Center, Miriam Hospital, Providence, RI, United States

Men's Health Center, Miriam Hospital Providence, 02901, Rhode Island, USA.

Brown University, Providence, RI.

2019

Men's Health Center, Department of Family and Community Medicine, Department of Family Medicine and Urology, Warren Alpert School of Medicine of Brown University, Providence, RI.

Departments of Family Medicine and Urology, Men’s Health Center, Miriam Hospital, Brown University, Providence, RI, USA

2018

American Urological Association Education and Research, Inc., Linthicum, Maryland.

Department of Family Medicine, Alpert Medical School of Brown University, Providence, RI (M.M.M.).

Warren Alpert School of Medicine, Brown University, Providence, RI, USA

2017

Providence, RI

2016

Brown University Providence RI USA

Men's Health Center, Providence, RI

2015

Department of Family Medicine, The Alpert Medical School of Brown University, Providence, Rhode Island, USA

2014

Brown University, Providence, Rhode Island, USA.

Men's Health Center, Chief of Family and Community Medicine, Miriam Hospital, 164 Summit Avenue, Providence, RI 02906, USA

2013

Miriam Hospital Men’s Health Center, Warren Alpert School of Medicine, Brown University Providence,

214 N. West Ave, 49201, Jackson, Michigan, USA

2012

Department of Family Medicine and Department of Urology, Warren Alpert School of Medicine, Brown University, Providence, RI

Miriam Hospital Men's Health Center, Warren Alpert School of Medicine, Brown University, Providence, Rhode Island, USA

2011

Miriam Hospital Men's Health Center, 164 Summit Avenue, Providence, RI 02906, USA

The International Society on Men’s Health Testosterone Consensus Group, Warren Albert School of Medicine, Brown University, Providence, RI

2010

Men's Health Center, the Miriam Hospital, and the Warren Alpert School of Medicine, Brown University, Providence, Rhode Island

Brown University School of Medicine, Providence, RI, USA;

Swansea Family Practice Group, Swansea, MA, USA

2009

Men's Health Center, The Miriam Hospital Providence, RI

Department of Family Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA

Men’s Health Center, Miriam Hospital, Warren Alpert Medical School, Brown University

2008

Men's Health Center, The Miriam Hospital, Warren Alpert School of Medicine, Brown University, Swansea, MA, USA;

Brown University, Department of Family Medicine, Providence,

2007

Division of Biology and Medicine, Department of Family Medicine, Warren Alpert Medical School of Brown University, Providence, RI, USA

Brown University School of Medicine, Providence, Rhode Island

2006

Department of Family Medicine, Brown Medical School, Providence, RI, USA

2005

Brown Medical School, Box G-A, Providence, RI 02912, USA

2004

Swansea Health Center, Swansea, MA, USA

Prominent publications by Martin M Miner

KOL-Index: 15437 . PURPOSE: We measured prostate specific antigen after 12 months of testosterone replacement therapy in hypogonadal men. MATERIALS AND METHODS: Data were collected from the TRiUS (Testim® Registry in the United States), an observational registry of hypogonadal men on testosterone replacement therapy (849). Participants were Testim naïve, had no prostate cancer and received 5 to 10 gm Testim ...
Known for Testosterone Replacement Therapy | Specific Antigen | 12 Months | Prostate Saturation Theory
KOL-Index: 13053 . INTRODUCTION: Up to 30% of erectile dysfunction (ED) patients treated with phosphodiesterase type 5 (PDE5) inhibitors do not show improved sexual function, which may be due in part to low serum testosterone. Hypogonadal patients already receiving testosterone replacement therapy (TRT) likewise can still suffer from symptoms of sexual dysfunction. In these patient populations, augmenting ...
Known for Sexual Function | United States | Testim Registry | Testosterone Replacement Therapy
KOL-Index: 12537 . INTRODUCTION: Cligosiban is an orally administered oxytocin receptor antagonist being developed to treat premature ejaculation (PE). AIM: To determine the safety and efficacy of cligosiban capsules (dose range 400-800 mg) to improve intravaginal ejaculation latency time (IELT) and patient-reported outcomes in men with severe lifelong PE. METHODS: Patients recorded details of at least 4 ...
Known for Oxytocin Antagonist | Ielt Cligosiban | Lifelong Premature | Intravaginal Ejaculatory
KOL-Index: 10825 . BACKGROUND: Recent evidence suggests that there may be a bidirectional, physiological link between hypogonadism and metabolic syndrome (MetS), and testosterone replacement therapy (TRT) has been shown to improve some symptoms of MetS in small patient populations. We examined the effect of 12 months of TRT on MetS components in a large cohort of hypogonadal men. METHODS: Data were obtained ...
Known for 12 Months | Testim Registry | Testosterone Replacement Therapy | Metabolic Syndrome
KOL-Index: 10589 . BACKGROUND: COVID-19 lung segmentation using Computed Tomography (CT) scans is important for the diagnosis of lung severity. The process of automated lung segmentation is challenging due to (a) CT radiation dosage and (b) ground-glass opacities caused by COVID-19. The lung segmentation methodologies proposed in 2020 were semi- or automated but not reliable, accurate, and user-friendly. The ...
Known for Lung Segmentation | Computed Tomography | Deep Learning | Vgg Segnet
KOL-Index: 10475 . INTRODUCTION: Female sexual function is dependent, in part, upon normal endothelial function within the genital arterial (hypogastric-cavernosal) vascular bed. The first two Princeton Consensus Conferences were focused on relationships between male sexual function and cardiovascular health, and development of contemporary clinical guidelines for dysfunction management. AIM: The third ...
Known for Sexual Health | Cardiometabolic Risk | Fsd Women | Cardiovascular Disease
KOL-Index: 10410 . OBJECTIVES: The severity of lower urinary tract symptoms (LUTS) has correlated with erectile dysfunction (ED) and ejaculatory dysfunction (EjD) in large-scale epidemiologic studies. ED and EjD are also side effects of some medical therapies for LUTS suggestive of benign prostatic hyperplasia (LUTS/BPH). These relationships were examined in a physician office-based population of men ...
Known for Sexual Dysfunction | Luts Bph | Lower Urinary | Tract Symptoms
KOL-Index: 10096 . BACKGROUND: Benign prostatic hyperplasia (BPH) is a common disorder in older men and may be associated with lower urinary tract symptoms (LUTS) and sexual dysfunction. Men who present with symptomatic BPH and LUTS are at increased risk for sexual dysfunction, including erectile dysfunction (ED) and ejaculatory dysfunction (EjD). OBJECTIVE: This review describes treatment options ...
Known for Sexual Function | Prostatic Hyperplasia | Luts Bph | Lower Urinary
KOL-Index: 9464 . OBJECTIVE: Among patients with hypogonadism-associated comorbidities, opioid users have the highest incidence of hypogonadism. Data from the Testim Registry in the United States were analyzed to determine the efficacy of testosterone replacement therapy in opioid users vs nonusers. DESIGN: Prospective, 12-month observational cohort registry. SUBJECTS: Hypogonadal men (N = 849) prescribed ...
Known for Opioid Users | Testosterone Replacement | United States | Sexual Function
KOL-Index: 9235 . INTRODUCTION: Phosphodiesterase type-5 (PDE-5) inhibitors have previously been evaluated for their efficacy and safety in various clinical trials in men with erectile dysfunction (ED) with or without associated comorbidities. AIM: This is the first prospective, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a PDE-5 inhibitor (i.e., vardenafil) in ...
Known for Vardenafil Placebo | Efficacy Safety | Sep2 Sep3 | Outcome Measures
KOL-Index: 8477 . BACKGROUND: Testosterone deficiency (TD) is prevalent among men seeking medical attention and may be associated with other comorbidities. OBJECTIVE: The Testim(®) Registry in the United States (TRiUS), a large, multicenter, prospective, 12-month observational cohort registry, was established to quantify symptoms and comorbidities of hypogonadal men in real-world clinical settings and to ...
Known for Trius Registry | Testosterone Deficiency | Baseline Data | Blood Glucose
KOL-Index: 8396 . BACKGROUND AND PURPOSE: Atherosclerotic plaque tissue rupture is one of the leading causes of strokes. Early carotid plaque monitoring can help reduce cardiovascular morbidity and mortality. Manual ultrasound plaque classification and characterization methods are time-consuming and can be imprecise due to significant variations in tissue characteristics. We report a novel artificial ...
Known for Artificial Intelligence | Stroke Risk | Symptomatic Plaque | Optimized Classification
KOL-Index: 8273 . PURPOSE: We examined the evaluation of and management for lower urinary tract symptoms/benign prostatic hyperplasia by physician specialty (urologist vs primary care physician). MATERIALS AND METHODS: The BPH Registry and Patient Survey is a longitudinal, observational, disease registry cohort of patients enrolled from January 2004 to February 2005 in the United States. The survey examines ...
Known for Prostatic Hyperplasia | Primary Physicians | United States | Urinary Tract
KOL-Index: 8240 . PURPOSE: Germline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary cancer assessment. Critical needs include optimized multigene testing strategies that incorporate evolving genetic data, consistency in GT indications and management, and alternate genetic evaluation models that address the rising demand for genetic services. METHODS: A ...
Known for Germline Testing | Prostate Cancer | Metastatic Pca | Atm Brca2
KOL-Index: 7939 . * A significant proportion of men with erectile dysfunction (ED) exhibit early signs of coronary artery disease (CAD), and this group may develop more severe CAD than men without ED (Level 1, Grade A). * The time interval among the onset of ED symptoms and the occurrence of CAD symptoms and cardiovascular events is estimated at 2-3 years and 3-5 years respectively; this interval allows for ...
Known for Coronary Artery | Erectile Dysfunction | Pde5 Inhibitors | Cardiovascular Disease

Key People For Erectile Dysfunction

Top KOLs in the world
#1
Raymond C Rosen†
erectile dysfunction sexual function premature ejaculation
#2
Irwin S Goldstein
erectile dysfunction smooth muscle sexual medicine
#3
John B McKinlay
erectile dysfunction metabolic syndrome boston area community health
#4
Tom F Lue
erectile dysfunction penile erection rat model
#5
Dimitrios G Hatzichristou
erectile dysfunction intracavernous injection 5 inhibitors
#6
Robert J Krane
blood flow smooth muscle chronic ischemia

Family Medicine and Urology, Warran Alpert Medical School, Brown University, Providence, Rhode Island, USA | Men’s Health Center, Miriam Hospital, Providence, RI 02906, USA;, martin_miner@brown.edu | Men's Health Center, Miriam Hospital Providence, R